tbuckley/cabot-search huggingface dataset:
FRI0571 The Association between Comorbidities and Disease Activity, Functional Ability and Quality of Life in Patients with Spondyloarthritis: Results from The Multi-National ASAS-Comospa Study: Table 1.
Authors: E. Nikiphorou, S. Ramiro, R. Landewé, A. Molto, M. Dougados, F. Van den Bosch, D. van der Heijde
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Comorbidities in rheumatoid arthritis are known to add to the burden of disease and its complexity, with implications on disease outcomes and prognosis. In Spondyloarthritis (SpA), the impact of comorbidities on outcomes is less well studied; yet, their prevalence is high. <h3>Objectives</h3> To investigate the relationship between the comorbidity burden in SpA as measured by the Rheumatic Disease Comorbidity Index (RDCI) and: (1) disease activity; (2) function; (3) quality of life. <h3>Methods</h3> Analysis was based on data from the ASAS COMOrbidities SPA study, ASAS-COMOSPA, a cross-sectional, multinational study involving 22 countries across four continents. Patients fulfilling the ASAS SPA criteria were included. Comorbidities were computed according to the Rheumatic Diseases Comorbidity Index (RDCI), which includes ischaemic heart disease, stroke, hypertension, lung disease (COPD), malignancy, fractures, depression, diabetes and gastrointestinal disease; range 0–9 (higher score indicating higher comorbidity burden). Univariable, followed by multivariable multilevel mixed-effects linear regression models were used to investigate the relationship between the RDCI and ASDAS(CRP), BASDAI, patient global, BASFI, and EQ5D, adjusting for clinical confounders (table). Patients were nested into their country of origin, which formed the basis of the multilevel analysis. <h3>Results</h3> A total of 3558 patients were included in the study; 66% males, mean age 43 (SD 14), median disease duration 5 years (IQR 11) and mean RDCI 0.72 (1.08). An increase in RDCI was associated with higher BASFI, BASDAI, ASDAS and patient global score and lower EQ5D (all p&lt;0.001) (see table). For instance a patient with an RDCI score of 2 compared to 0 had on average 0.7 point higher on the BASFI, one point higher on the BASDAI and patient global, 0.24 units higher on the ASDAS and a 0.06 points lower on the EQ-5D. <h3>Conclusions</h3> Higher comorbidity burden is independently associated with worse outcomes in SpA as reflected by higher disease activity, worse functional and quality of life measures. The results highlight the need for promptly identifying and treating comorbidities in SpA. As with emerging evidence in RA suggesting failure to achieve treat-to-target principles in the presence of comorbidities, it is possible that comorbidities also hinder the achievement of therapeutic goals in SpA. <h3>Disclosure of Interest</h3> None declared
Non-Hodgkin’s Lymphoma in the Context of Antecedent Rheumatoid Arthritis: A Case Series from the Mayo Clinic and the Nebraska Lymphoma Study Group.
Authors: Justin O. Endo, Melissa G.M. Ooi, Natalie A. Black, Patricia Aoun, Thomas M. Habermann, Julie A. Stoner, James O. Armitage, Ted R. Mikuls
Journal: Blood (2004)
Late Relapse in Hodgkin Lymphoma (HL): A Retrospective Analysis of Patients Enrolled on Clinical Trials at the Istituto Nazionale Tumori of Milan (INT-MI)
Authors: Simonetta Viviani, Alberto Mussetti, Oreste Di Bartolo, Antonello Cabras, Pinuccia Valagussa, Gianni Bonadonna, Alessandro M. Gianni, Paolo Corradini
Journal: Blood (2015)
P1.36: Non-Small-Cell Lung Cancer and Brain Metastases in Brazil
Authors: Luiza N. Weis, Juliano C. Coelho, Patrícia Marks, Guilherme Geib, Pedro Liedke, Rodrigo Pereira, Gilberto Schwartsmann, Sérgio Azevedo
Journal: Journal of Thoracic Oncology (2016)
The Prophylactic Use of G-CSF During Induction and Consolidation of Adults with Acute Lymphoblastic Leukemia Is Associated with Reduced Risk of Relapse and Improved Leukemia-Free Survival. A Joint Analysis of Five Randomized Trials on Behalf of the European Working Group for Adult ALL (EWALL)
Authors: Sebastian Giebel, Xavier Thomas, Helene Hallbook, Klaus Geissler, Jean-Michel Boiron, Françoise Huguet, Bengt Smedmyr, Elisabeth Koller, Andrzej Hellmann, Jerzy Holowiecki
Journal: Blood (2010)
Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis
Authors: Xiaoping Long, Xuan He, Shinichiro Ohshimo, Matthias Griese, Rafael Sarria, Josune Guzman, Ulrich Costabel, Francesco Bonella
Journal: European Respiratory Journal (2016)

YKL-40, a chitinase-like protein mainly secreted by macrophages, neutrophils and epithelial cells, is increased in patients with idiopathic interstitial pneumonia and sarcoidosis. We aimed to investigate the role of YKL-40 as a biomarker in hypersensitivity pneumonitis (HP). 72 HP patients, 100 interstitial lung disease (ILD) controls and 60 healthy controls were studied. YKL-40 was measured by ELISA in serum and bronchoalveolar lavage fluid (BALF) at baseline and follow-up. The relationship between YKL-40 levels, clinical variables and disease outcome was evaluated. Baseline serum YKL-40 levels were significantly higher in HP patients than in healthy controls (p&lt;0.001), but lower than in patients with other ILDs. Baseline BALF YKL-40 levels in HP patients were the highest among ILD patients. In HP patients, serum YKL-40 correlated with the diffusing capacity of the lung for carbon monoxide at baseline (p&lt;0.01) and over time (p&lt;0.001). HP patients whose disease progressed or who died had higher baseline YKL-40 levels than those who remained stable and survived (p&lt;0.001). At a cut-off of 119 ng·mL −1 , the baseline serum YKL-40 level predicted disease progression (hazard ratio 6.567; p&lt;0.001), and at a cut-off of 150 ng·mL −1 was associated with mortality (hazard ratio 9.989; p&lt;0.001). Serum YKL-40 may be a useful prognostic biomarker in HP patients.
Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Multiple Myeloma.
Authors: Deborah S Ricci, Reyna Favis, Yu Sun, Helgi van de Velde, Erin Broderick, Michael Meyers, Jean-Luc Harousseau, Hervé Avet-Loiseau, Paul G Richardson, Jesús F San Miguel
Journal: Blood (2009)
Tryptophan hydroxylase 1 and 5-HT7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling
Authors: Jaya Gautam, Suhrid Banskota, Sushil Chandra Regmi, Subi Ahn, Yong Hyun Jeon, Hyunyoung Jeong, Seung Joo Kim, Tae-gyu Nam, Byeong-Seon Jeong, Jung-Ae Kim
Journal: Molecular Cancer (2016)

Triple-negative breast cancer (TNBC) has a high risk of relapse and there are few chemotherapy options. Although 5-hydroxytryptamine (5-HT, serotonin) signaling pathways have been suggested as potential targets for anti-cancer drug development, the mechanism responsible for the action of 5-HT in TNBC remains unknown.Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting were used to measure mRNA and protein levels, respectively. Cell proliferation was measured using CellTiter 96 Aqueous One Solution. siRNA transfection was used to assess involvement of genes in cancer invasion, which were identified by Matrigel transwell invasion assay. Levels of 5-HT and vascular endothelial growth factor (VEGF) were measured using ELISA kits. Chick chorioallantoic membrane (CAM) assay and mouse tumor model were used to investigate the in vivo effects of SB269970, a 5-HT7 receptor antagonist, and BJ-1113, a novel synthetic compound.TNBC cell lines (MDA-MB-231, HCC-1395, and Hs578T) expressed higher levels of tryptophan hydroxylase 1 (TPH1) than hormone-responsive breast cancer cell lines (MCF-7 and T47D). In MDA-MB-231 cells, 5-HT promoted invasion and proliferation via 5-HT7 receptor, and interestingly, the stimulatory effect of 5-HT on MDA-MB-231 cell invasion was stronger than its effect on proliferation. Likewise, downstream signaling pathways of 5-HT7 differed during invasion and proliferation, that is, Gα-activated cAMP and Gβγ-activated kinase signaling during invasion, and Gβγ-activated PI3K/Akt signaling during proliferation. Also, 5-HT increased the protein expressions of TPH1 and VEGF in MDA-MB-231 cells. These results provide insight of the stimulatory effect of 5-HT on breast cancer progression; 5-HT was found to act more strongly during the first stage of metastasis (during invasion and migration) than during the later proliferative phase after local invasion. Interestingly, these actions of 5-HT were inhibited by BJ-1113, a 6-amino-2,4,5-trimethylpyridin-3-ol analog. BJ-1113 blocked intracellular signaling pathways initiated by 5-HT7 receptor activation, and exhibited anti-proliferative and anti-invasive activities against MDA-MB-231 cells. Furthermore, the inhibitory effect of BJ-1113 against MDA-MB-231 tumor growth was greater than that of SB269970, a 5-HT7 receptor antagonist.5-HT7 receptor which mediates 5-HT-induced cancer progression is a potential therapeutic target in TNBC, and BJ-1113 offers a novel scaffold for the development of anti-cancer agents against TNBC.
Vasectomy and Cancer of the Cervix
Authors: R W Harris, W A Scott
Journal: New England Journal of Medicine (1979)

Swan and Brown in a recent issue of the New England Journal of Medicine reported a lower rate of sterilization among patients with cervical cancer or their partners than among matched controls. The major part of this difference was attributed to vasectomies, since 4.3% of patients with cervical cancer, as compared with 19.4% of matched controls, had partners who had undergone a vasectomy. Although Swan and Brown claimed that this difference persisted "after adjusting for sexual factors," no information was provided on the number of sexual partners of the subjects or whether all partners had undergone vasectomy. In a recent study of the role of sexual factors in cancer of the cervix uteri and its precursors in a group of 278 women with cervical cancer or dysplasia and 502 controls, these researchers found that sterilizatons among these patients or any of their partners (8.6%) were less common than among controls (11.5%). Tubal ligations failed to account for this difference. 2.9% of the patients had partners who had undergone vasectomy, as compared with 7.2% of the control women. After adjusting for number of partners, it was found that the relative risk of cervical cancer in women who had only 1 partner, who had had a vasectomy, was 1.17 times that in women with only 1 partner, who had not had a vasectomy. The relative risk in women with several partners without vasectomies was 4.62 times that in women with several partners, 1 of whom had undergone a vasectomy. Although it would be expected that if vasectomy had a protective effect, there would have been a statistically significant relative risk in women with 1 partner only, who had not undergone vasectomy, this risk was not found.
Reply to ‘A phase <scp>II</scp> randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients’
Authors: O. Yélamos, A.C. Halpern, M.A. Weinstock
Journal: British Journal of Dermatology (2016)

We have read with interest the paper by Chen et al. in which oral nicotinamide is used to prevent keratinocyte carcinomas (KC; basal and squamous cell carcinomas of the skin) in renal transplant patients.1 The current study suggests nicotinamide is safe and effective to prevent the development of KC in this high-risk group, similarly to a study by the same group in non-transplant patients (ONTRAC study, Oral Nicotinamide To Reduce Actinic Cancer).

This article is protected by copyright. All rights reserved.
IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era
Authors: Matthew J Maurer, Herve Ghesquieres, Jean-Philippe Jais, Thomas E Witzig, Corinne Haioun, Carrie A Thompson, Richard Delarue, Ivana N. Micallef, Frederic Peyrade, William R Macon, Thierry Jo Molina, Nicolas Ketterer, Sergei I Syrbu, Olivier Fitoussi, Paul J Kurtin, Cristine Allmer, Emmanuelle Nicolas-Virelizier, Susan L Slager, Thomas M Habermann, Brian K Link, Gilles Andre Salles, Herve Tilly, James R Cerhan
Journal: Blood (2013)
Nanotopography controls cell cycle changes involved with skeletal stem cell self-renewal and multipotency
Authors: Louisa C.Y. Lee, Nikolaj Gadegaard, María C. de Andrés, Lesley-Anne Turner, Karl V. Burgess, Stephen J. Yarwood, Julia Wells, Manuel Salmeron-Sanchez, Dominic Meek, Richard O.C. Oreffo, Matthew J. Dalby
Journal: Biomaterials (2016)

In culture isolated bone marrow mesenchymal stem cells (more precisely termed skeletal stem cells, SSCs) spontaneously differentiate into fibroblasts, preventing the growth of large numbers of multipotent SSCs for use in regenerative medicine. However, the mechanisms that regulate the expansion of SSCs, while maintaining multipotency and preventing fibroblastic differentiation are poorly understood. Major hurdles to understanding how the maintenance of SSCs is regulated are (a) SSCs isolated from bone marrow are heterogeneous populations with different proliferative characteristics and (b) a lack of tools to investigate SSC number expansion and multipotency. Here, a nanotopographical surface is used as a tool that permits SSC proliferation while maintaining multipotency. It is demonstrated that retention of SSC phenotype in culture requires adjustments to the cell cycle that are linked to changes in the activation of the mitogen activated protein kinases. This demonstrates that biomaterials can offer cross-SSC culture tools and that the biological processes that determine whether SSCs retain multipotency or differentiate into fibroblasts are subtle, in terms of biochemical control, but are profound in terms of determining cell fate.
PWE-113 One Year Experience of A New Chronic Radiation Proctopathy Specialist Service
Authors: N O’shea, S Thomas-Gibson, A Wilson
Journal: Gut (2016)

<h3>Introduction</h3> Chronic radiation proctopathy (CRP) is a recognised complication of pelvic radiotherapy. Symptoms include diarrhoea, rectal pain, bleeding and tenesmus. In 2014, we set up an enhanced, dedicated, multidisciplinary, specialist service for managing the gastro-intestinal (GI) complications of CRP, based on The Royal Marsden Protocol.<sup>1</sup> Here we review the management of CRP at a tertiary referral centre over one year. <h3>Methods</h3> Patients with CRP reported at lower GI endoscopy (December 2014–15), were identified by an Endoscopy Database search for ‘radiation’. Case notes were reviewed. Indication for procedure, previous cancer and radiotherapy, endoscopy findings, treatment and outcomes were recorded. <h3>Results</h3> 86 patients had endoscopic evidence of CRP. M:F ratio 8:1. Cancer history: prostate 87% (75), cervical 6% (5), rectal 4% (3), bladder 1% (1), ovarian 1% (1), endometrial 1% (1). Mean time since radiotherapy: 4.5 years (range: 1–13 years). 24% (21) were referred via the 2 WW pathway and 16% (14) by the bowel cancer screening program (BCSP). 23% (20) were identified during surveillance colonoscopies for cancer/ polyps or colitis. 36% (31) were referred from GI clinic. Indications: rectal bleeding 47% (40), change in bowel habit 5% (4), iron deficiency anaemia (IDA) 8% (7) and faecal occult blood 16% (14). 41% (35) were asymptomatic. 27% (23) required intervention for CRP (haemorrhagic angiectasia with rectal bleeding causing anaemia and/or significant impact on quality of life). Sucralfate enemas 2 g bd, ± metronidazole oral 400 mg tds, ± Normacol were prescribed. 65% (15/23) were referred to a Specialist Nurse for follow up, 53% (8/15), of which, responded to medical therapy within 8 weeks. One patient was unable to tolerate sucralfate enemas. 13% (3/23) patients required escalation to rectal formalin instillation. ‘<i>Off protocol’,</i>7% (6) were treated with Argon Plasma Coagulation (APC) as their index therapy. A solitary rectal ulcer was found in 5% (4) of patients, two were a complication of APC. Two patients were referred for hyperbaric oxygen therapy. 62% of patients did not require any therapeutic intervention. <h3>Conclusion</h3> A significant number of patients with CRP are now referred via 2 WW and BCSP. Full colonoscopic assessment is appropriate to exclude other pathology, however, the majority do not require medical or endoscopic intervention, many are asymptomatic and few have IDA. For patients that require intervention for CRP, a multidisciplinary approach should be employed, medical therapy is effective and well tolerated, endoscopic intervention should be reserved for individuals who fail medical treatment. APC should only be used in carefully selected cases due to risk of ulceration. CRP services should be audited to ensure appropriate management and minimise complications. <h3>Reference</h3> 1 <i>Frontline Gastroenterol</i> (2015) <b>6</b> (1): 53–72. <h3>Disclosure of Interest</h3> None Declared
Further Evidence to Not Delay Transplant for Continued ARA-C Consolidation in Patients with Intermediate or High Risk AML
Authors: James K. Feisal, Nicholas B. Pleat, Michael Machiorlatti, Summer Frank, Sara Vesley, Sarah Schmidt, George Selby, Carrie Yuen, Jennifer L Holter-Chakrabarty, Mohamad Cherry, Mohamad Khawandanah
Journal: Blood (2015)
Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk
Authors: Philip C. Amrein, Eyal C Attar, Tak Takvorian, Ephraim Hochberg, Karen K Ballen, Kathleen M Leahy, David C. Fisher, Ann LaCasce, Eric D Jacobsen, Philippe Armand, Robert Hasserjian, Lillian Werner, Donna Neuberg, Jennifer R Brown
Journal: Blood (2010)
The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era.
Authors: Moccia A. Moccia, Jane Donaldson, Mukesh Chhanabhai, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Brian Skinnider, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn
Journal: Blood (2009)
Erratum to “The SCARE guidelines: Consensus-based surgical case report guidelines” [Int. J. Surg. 34 (2016) 180–186]
Authors: Riaz A. Agha, Alexander J. Fowler, Alexandra Saeta, Ishani Barai, Shivanchan Rajmohan, Dennis P. Orgill, Raafat Afifi, Raha Al-Ahmadi, Joerg Albrecht, Abdulrahman Alsawadi, Jeffrey Aronson, M.Hammad Ather, Mohammad Bashashati, Somprakas Basu, Patrick Bradley, Mushtaq Chalkoo, Ben Challacombe, Trent Cross, Laura Derbyshire, Naheed Farooq, Jerome Hoffman, Huseyin Kadioglu, Veeru Kasivisvanathan, Boris Kirshtein, Roberto Klappenbach, Daniel Laskin, Diana Miguel, James Milburn, Seyed Reza Mousavi, Oliver Muensterer, James Ngu, Iain Nixon, Ashraf Noureldin, Benjamin Perakath, Nicholas Raison, Kandiah Raveendran, Timothy Sullivan, Achilleas Thoma, Mangesh Thorat, Michele Valmasoni, Samuele Massarut, Anil D'cruz, Vasudevan Baskaran, Salvatore Giordano, Gaurav Roy, Donagh Healy, David Machado-Aranda, Bryan Carroll, David Rosin
Journal: International Journal of Surgery (2016)
AB0200 CYP2C9 Activity in Turkish Patients with Rheumatoid Arthritis
Authors: E.K. Ozer, I. Albayrak, M.T. Goktas
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> <i>Rheumatoid arthritis</i> (RA) is a chronic, autoimmune, multisystemic, inflammatory and common disease with unknown etiology. <i>Cytochrome</i> P450 2C9 (CYP2C9) is responsible for up to 40 drugs metabolism in the liver such as oral anticoagulants (warfarin), oral antidiabetics (tolbutamide, glyburide), angiotensin II receptor antagonists (losartan, irbesartan), phenytoin (1). Most of the drugs convert to active or inactive metabolites by CYP2C9. In a recent study Goktas MT <i>et al</i>. showed that CYP2C9 activity reduced in Behçet9s disease that an autoimmune disease (2). <h3>Objectives</h3> This study aimed to investigate activity of CYP2C9 in patients with RA. <h3>Methods</h3> Losartan and its metabolite (E-3174) concentrations were analysed in healthy subjects (n=38) and RA patients (n=32) urine by high-performance liquid chromatography (HPLC). A acetonitrile and 66/34 mixture of phosphate tamponate (NaH2PO4, 15 mM, pH=2.8) were used as mobile phase. Urine samples in mobile phase and isopropanol (2/1/1 in volume, respectively) were injected into Agilent Eclipse XDB-C18 (5 μm, 4.6x150 mm) column via Agilent Technologies 1200 HPLC system (Agilent Technologies, Waldbron, Germany). Losartan and its metabolite E-3174 were detected via a UV detector at 245 nm. The inter- and intra-day coefficient of variation (CV) was less than %4 for losartan and its metabolite. The ratio of losartan to its metabolite (E-3174) was calculated (metabolic ratio, MR) and used as a marker of the activity of the CYP2C9 enzyme. <h3>Results</h3> MR (losartan/its metabolite ratio) was increased in RA patients from 1.34±0.22 to 1.75±0.31. This result shows that CYP2C9 activity decreased in RA patients compared with healthy subjects. <h3>Conclusions</h3> CYP2C9 activity decreased in RA patients so we must be carefully when using the drugs that metabolized with CYP2C9. The efficacy of some treatments would be compromised in RA patients because they were given drugs in dosages that might be ineffective or cause adverse drug reaction and toxicity. This study is continued at other centers. <h3>References</h3> Hatta FH, Teh LK, Helldén A, Hellgren KE, Roh HK, Salleh MZ, Aklillu E, Bertilsson L. Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8–109A&gt;T and the losartan metabolism phenotype in Swedes. Eur J Clin Pharmacol. 2012;68(7):1033–42. Goktaş MT, Hatta F, Karaca O, Kalkisim S, Kilic L, Akdogan A, Babaoglu MO, Bozkurt A, Helldén A, Bertilsson L, Yasar U. Lower CYP2C9 activity in Turkish patients with Behçet9s disease compared to healthy subjects: a down-regulation due to inflammation? Eur J Clin Pharmacol. 2015;71(10):1223–8. <h3>Disclosure of Interest</h3> None declared